Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments

37:34
 
Share
 

Manage episode 407613855 series 2991382
Content provided by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Guests: Pete Bak and Christian Thienel

Length: 37 minutes

With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccines, but other companies riding the tailwind and developing vaccine therapies that span across viral illness, maternal infections and bacterial infections.

In this episode resident immunologist Dr. Pete Bak and Christian Thienel discuss vaccine technology, up-and-coming areas of interest, such as RSV, and the vaccines currently in late-stage clinical development.

Topics in this podcast include:

  • Vaccine technology, vaccine types and their varying levels of durability
  • The ongoing interest of vaccine development for RSV, including data from GSK’s Arexvy and Pfizer’s Abrysvo vaccines
  • How recommendations from the Advisory Committee on Immunization Practices (ACIP) influence commercial dynamics
  • The interesting chess game of scheduling vaccines as they relate to COVID, flu and RSV (seasonality versus strains and antigens)
  • Vaccine development and data as it applies to Cytomegalovirus (CMV) and Epstein-Barr (EBV)
  • News from the bacterial front: MinervaX leading the way with a maternal vaccine against Group B streptococcus infections with a very large series B round for $54M; Pfizer’s recent Prevnar 20 against pneumococcal pneumonia
  • Pricing, reimbursement and the interplay with ACIP guidelines

As always, we welcome listener questions and/or topics you’d like to learn more about.

You can listen to previous episodes here or submit your inquiries here.

  continue reading

32 episodes

Artwork
iconShare
 
Manage episode 407613855 series 2991382
Content provided by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Guests: Pete Bak and Christian Thienel

Length: 37 minutes

With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccines, but other companies riding the tailwind and developing vaccine therapies that span across viral illness, maternal infections and bacterial infections.

In this episode resident immunologist Dr. Pete Bak and Christian Thienel discuss vaccine technology, up-and-coming areas of interest, such as RSV, and the vaccines currently in late-stage clinical development.

Topics in this podcast include:

  • Vaccine technology, vaccine types and their varying levels of durability
  • The ongoing interest of vaccine development for RSV, including data from GSK’s Arexvy and Pfizer’s Abrysvo vaccines
  • How recommendations from the Advisory Committee on Immunization Practices (ACIP) influence commercial dynamics
  • The interesting chess game of scheduling vaccines as they relate to COVID, flu and RSV (seasonality versus strains and antigens)
  • Vaccine development and data as it applies to Cytomegalovirus (CMV) and Epstein-Barr (EBV)
  • News from the bacterial front: MinervaX leading the way with a maternal vaccine against Group B streptococcus infections with a very large series B round for $54M; Pfizer’s recent Prevnar 20 against pneumococcal pneumonia
  • Pricing, reimbursement and the interplay with ACIP guidelines

As always, we welcome listener questions and/or topics you’d like to learn more about.

You can listen to previous episodes here or submit your inquiries here.

  continue reading

32 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play